Navigation Links
"Over the Next 2-3 Years We Will Leverage Developmental Capabilities and Explore In-licensing and a Co-development Model to Consolidate Our Presence in Japan" - Dr. Kailash Sharma, President, Japan Operations, Zydus Cadila
Date:7/30/2009

TOKYO, July 30 /PRNewswire/ -- With a business plan to launch 8-10 new products each year, Nippon Universal Pharmaceutical Co. Ltd., a subsidiary of the Zydus group, one of India's leading integrated pharma companies & a global healthcare provider, is looking to give a big boost to its operations in the Japanese generic market which is still evolving. While the total pharma market in Japan is estimated at $ 60 bn the generic market is only about 6% of this in value terms and just 18% in volume, which is very low compared to highly genericised markets like USA and Europe. The awareness of generics in Japan is comparatively low and generics are still largely perceived as cheaper, low quality alternatives to patented drugs. The nationwide promotion and awareness campaign regarding the safety and efficacy of generics however is expected to change this perception and usage in future.

Zydus was one of the few Indian companies to make an early foray in the Japan generic market. In 2007, the group acquired Nippon Universal, a small generic company which now spearheads the group's operations in Japan.

"Our aim clearly is to support the government's stated objective of increasing generic penetration in order to cope up with ever increasing health expenditures. Over the next 2-3 years we will leverage developmental capabilities and explore in-licensing and a co-development model to consolidate our presence in Japan", said Dr. Kailash Sharma, the newly appointed President to spearhead operations in Japan.

Being one of the few pharma professionals who can combine research, strategy and marketing expertise, Dr. Kailash Sharma is much sought after. Dr. Kailash Sharma with over 13 years of experience in the Japan's pharma industry will be steering the group's operations in this crucial growth phase. With a doctorate in Cell & Molecular Biology from Kurume University Medical School, Japan and an Executive MBA from Temple University, Philadelphia, USA, Dr. Sharma has earlier worked with Eisai, Nippon Boehringer Ingelheim and Sanofi - Aventis, Japan and has successfully managed the core functions in all phases of drug development cycles. Last but not least, being in Japan for about 20 years, first as a doctorate researcher and then as a pharmaceutical professional, Dr. Sharma is very well familiar and have respect for Japanese culture, legal system, quality standards, regulatory guidelines and business practices in Japan.

With a focus on quality medicines, Nippon Universal will be leveraging Zydus' capabilities in oral solids, injectables, biosimilars etc. While ramping up the product pipeline is important, the group's strategy would be more country specific and focus on the unmet needs in the Japanese market. elaborating on the group's approach, Dr. Sharma said "We believe that there is a growing need for high quality, affordable therapies while reducing the healthcare cost burden. We are looking to combine expertise with adaptability. Understanding specific market needs and backing it up with customer centric approach will form the core of our strategy." The group plans to post sales of Yen 20 billion in Japan by 2015.


'/>"/>
SOURCE Zydus Cadila
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Aware Celebrates Fifteen Years of Innovation and Leadership in the Biometrics Industry
2. Social Network for Scientists Marks Ten Years Online
3. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
4. Dark energy -- 10 years on
5. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
6. Biotech Crops Experience Remarkable Dozen Years of Double-Digit Growth
7. Electrophysiology Procedures for Atrial Fibrillation Treatment to Grow Over 25% Annually Over the Next Five Years
8. Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations
9. Graphene-based gadgets may be just years away
10. Direct Medical Systems Reaches Profitability in 2-1/2 Years, as a Result of Sales of the Worlds Smallest and Lightest Ultrasound System, the InNovaSound USB Ultrasound.
11. CBO: Biogenerics Would Save Federal Government $6.6 Billion Over Ten Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):